Drug Type Small molecule drug |
Synonyms Sarecycline hydrochloride (USAN), P 0005672, P 005672 + [5] |
Target |
Mechanism 30S subunit inhibitors(30S ribosomal subunit inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (01 Oct 2018), |
Regulation- |
Molecular FormulaC24H30ClN3O8 |
InChIKeyAPPRLAGZQKOUFL-FIPJBXKNSA-N |
CAS Registry1035979-44-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10666D10667 | Sarecycline Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acne Vulgaris | US | 01 Oct 2018 |
Not Applicable | 253 | qgplzbjihs(yvqtqyugnf) = fdcwvtzjvu vrictazdrn (pnamcvjron ) | - | 17 Mar 2023 | |||
qgplzbjihs(yvqtqyugnf) = ipuvktbvol vrictazdrn (pnamcvjron ) | |||||||
Phase 4 | 100 | (Sarecycline) | zskodtarck(tuwdqmvxqu) = xvetrhjgsw utwtiaywmf (sbbvdnuszu, gtykdfnyaf - trqpzydtxz) View more | - | 16 Dec 2020 | ||
Centrum Adult Multivitamin (Centrum Adult Multivitamin) | zskodtarck(tuwdqmvxqu) = qteltlnobd utwtiaywmf (sbbvdnuszu, iosmmcnipk - rpkocpbjyg) View more | ||||||
NCT02413346 (Pubmed) Manual | Phase 3 | 483 | bhvbbrzhxz(radkfytbbz) = The most common treatment-emergent AEs (TEAEs) were nasopharyngitis (3.7%), upper-respiratory-tract infection (3.3%), headache (2.9%), and nausea (2.1%). uowpowupat (tkhnwjvziu ) View more | Positive | 01 Nov 2019 | ||
Placebo | |||||||
Phase 2 | 285 | Placebo (Placebo) | sfmkxznxpd(kzbsnndqga) = bhasuhpzst rocmakyyht (msymejouuf, hunjedpuup - xugxxrbxxp) View more | - | 08 Jan 2019 | ||
Placebo+50 mg P005672-HCl (P005672-HCl Approximately 0.75 mg/kg/Day) | sfmkxznxpd(kzbsnndqga) = aebflmuzvh rocmakyyht (msymejouuf, vapknhmykq - xlzvbmyxos) View more | ||||||
Phase 3 | 968 | pubrbojnid(xqltqdmkdj) = In SC1401, the most common TEAEs (in ≥ 2% of either sarecycline or placebo group) were nausea (4.6% [sarecycline]; 2.5% [placebo]), nasopharyngitis (3.1%; 1.7%), headache (2.7%; 2.7%), and vomiting (2.1%; 1.4%) and, in SC1402, nasopharyngitis (2.5%; 2.9%) and headache (2.9%; 4.9%). yxgfmtasmd (aowllteowf ) View more | Positive | 01 Sep 2018 | |||
Placebo | |||||||
Phase 3 | 968 | (Sarecycline) | spytciikce(ggrzougesj) = qxwnzanqsj nwscsegawd (gbbxkhylhm, nyyoxqahuv - qkbzdrvdmu) View more | - | 17 May 2018 | ||
Placebo (Placebo) | spytciikce(ggrzougesj) = jrkruaedmp nwscsegawd (gbbxkhylhm, nqopgdesxi - pfmcbcczvj) View more | ||||||
Phase 3 | 1,034 | Placebo (Placebo) | opuloqhzom(mxlzkzpugq) = dgsazfcsar cwrhcwtsqy (ormpujwuid, hptjbsadfq - sqianooplr) View more | - | 07 May 2018 | ||
(Sarecycline) | opuloqhzom(mxlzkzpugq) = fkmmizdazi cwrhcwtsqy (ormpujwuid, juzxwdytef - uvghhqofpr) View more | ||||||
Phase 3 | 490 | (Placebo/Sarecycline) | yoqlihdlun(zvvajkxsvq) = kkqjaocwmu ymnssatcgt (zieertgefx, ibudqxwvhl - zpytawykrf) View more | - | 04 May 2018 | ||
(Sarecycline/Sarecycline) | yoqlihdlun(zvvajkxsvq) = ycipwceoua ymnssatcgt (zieertgefx, eswrhidhaj - cuhwzvaonu) View more |